GlucaPharm Inc.
Tracked across 1 events · 7 articles · First seen May 12, 2026 · Last active May 14, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Impact: GlucaPharm Inc., a subsidiary of SureNano Science, is the developer of the GEP-44 peptide, a key asset in SureNano Science's GLP-1 platform.
May 12, 2026 · 7 articles
ERGEN INTELLIGENCE
Track GlucaPharm Inc. live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard